With regard to the therapeutic effects of EGFR-TKIs in EGFR mutation-positive NSCLC, PFS was found to differ depending on the mutation subtype (Ex19del or L858R), and PFS tended to be longer in patients with Ex19del than in those with Ex21 L858R, regardless of the EGFR-TKI therapies received (osimertinib and standard TKIs)12. Here, EGFR is linked to non-small cell lung carcinoma.